Articles tagged with Positron Emission Tomography
A new PET radiotracer can detect a wide range of mold species linked to life-threatening infections in cancer and transplant patients. The imaging agent, 18F-FDS, has the potential to dramatically enhance diagnosis and monitoring of invasive mold infections.
A new peptide-based PET tracer outperforms FDG PET in measuring PD-L1 expression in head and neck cancers. The tracer's uptake strongly correlates with PD-L1 levels, suggesting its potential for personalized treatment strategies.
Researchers developed a novel PET tracer targeting phosphodiesterase 4B to visualize real-time brain inflammation. The tracer showed superior image quality and greater brain distribution compared to existing tracers, highlighting its potential for early diagnosis and personalized therapy in neurodegenerative diseases.
A newly developed cardiac PET imaging technique offers a simpler way to detect significant coronary artery disease by eliminating the need for complex scanning protocols. The technique has been shown to accurately estimate myocardial flow reserve during both exercise and pharmacologic stress, making advanced heart imaging more accessible.
A novel integrated molecular imaging approach using dual PET/MR and PET/CMR techniques enables precise localization of heart damage and accurate identification of disease subtypes. This method also provides direct evidence supporting surgery as a cardio-protective intervention in patients with primary aldosteronism.
Wynn Volkert, a renowned expert in nuclear medicine, has been awarded the 2025 SNMMI Georg Charles de Hevesy Nuclear Pioneer Award. He made significant contributions to radiopharmaceutical development, including FDA-approved agents for brain and bone imaging.
Cybil Nielsen has been elected as the new president of the SNMMI Technologist Section, with a focus on expanding educational programs, mentorship opportunities, and networking events. She aims to promote the recognition and advancement of nuclear medicine technologists within the healthcare landscape.
Shannon Youngblood, a seasoned nuclear medicine professional, has been elected as President-Elect of the SNMMI Technologist Section. She aims to elevate visibility and recognition for nuclear medicine professionals through advocacy, promote diversity and inclusion in the workforce, and advance education and professional development. Wi...
A new PET imaging technique has successfully visualized three radiotracers in a single scan, enabling a more comprehensive molecular profile of disease. This innovation offers the potential to deliver greater precision in both diagnosis and therapeutic assessment, particularly for complex diseases like cancer.
A new brain imaging platform combining upright PET scanning, AR eye tracking, and motion tracking enables researchers to study brain function in a more natural and dynamic way. This approach offers a more realistic view of brain activity, holding promise for earlier detection of cognitive disorders.
Advanced software is used to measure radiation dose distribution throughout the body, ensuring patient safety and tailoring treatments. Post-therapy imaging helps identify complications and guide clinical decisions, ultimately optimizing treatment outcomes and protecting patients.
Two new PET imaging agents have been developed to identify the histamine H3 receptor, which regulates learning, memory, and sleep. These novel tracers show high brain uptake, excellent specificity, and improved in vivo stability.
Researchers found that low blood flow at rest may predict heart failure or death, while low stress flow may indicate heart attack risk. A new PET scan method also showed promise for Alzheimer's detection with high accuracy and minimal discomfort.
A novel immuno-PET/CT imaging technique has identified a potent biomarker for nasopharyngeal cancer (NPC), CD70, which is highly expressed in NPCs. The technique showed 100% detection rate of primary tumors and 93% detection rate of local lymph node metastasis in patients with early-stage disease.
Research found that approximately 50% of participants with late-life depression and bipolar disorder showed tau accumulation in their brains, compared to only about 15% of healthy controls. The study suggests that neurodegenerative diseases, including Alzheimer's, can initially manifest as psychiatric symptoms.
New radioimmunotherapy approaches show promise against advanced breast cancer and prostate cancer. Additionally, new imaging tools enhance cancer detection and diagnosis, while a proposed standard improves lesion interpretation. Cost-effectiveness studies also support novel therapies for rare digestive cancers.
A newly developed molecular imaging technique can identify multiple subtypes of triple-negative breast cancer, improving diagnostic capacity. The approach targets extra domain A of fibronectin, a stable protein in the tumor stromal environment abundantly expressed in breast cancer.
Researchers studied obesity's impact on breast cancer, linked imaging patterns to lung disease survival, and tracked hidden inflammation in COVID-19 patients using advanced PET imaging techniques.
Scientists have developed a novel pretargeting system to boost cancer imaging using DARPin G3, which achieves specific tumor targeting with reduced kidney and liver uptake. GRPR is emerging as a powerful tool for both imaging and treatment in various cancers, offering personalized cancer care across multiple tumor types.
Researchers at University of Turku discovered a new biomarker that correlates the thickness of inflammatory cell rim surrounding brain lesions with disease severity and speed. The wider the rim, the more aggressively the disease advances, allowing for earlier treatment identification and evaluating drug candidates.
Researchers developed promising α-synuclein PET tracers that can visualize protein aggregates in living patients, enabling earlier diagnosis and treatment monitoring. Tracers like [18F]C05-05 and [18F]ACI-12589 showed significant results in distinguishing synucleinopathies from healthy controls.
Adding an experimental cancer drug to standard TB treatment reduces lung damage and prevents post-TB lung disease in mice. Researchers found that the drug doubled pulmonary apoptosis and reduced lung scarring by 40% compared to standard treatments.
Researchers have developed novel imaging agents targeting shared proteins in triple-negative breast cancer tumors, successfully highlighting various tumor types using PET/CT scans. Additionally, a new brain imaging technique shows promise in identifying complex brain diseases like progressive supranuclear palsy and corticobasal degener...
A new study found that listening to favorite music activates the brain's opioid receptors, explaining why it evokes strong feelings of pleasure. The release of opioids is also linked to individual differences in music enjoyment and may help develop new music-based interventions for pain management and mental health disorders.
The SNMMI Mars Shot Research Fund has awarded a $100,000 fellowship to Dr. Randy Ye for his research on FAPI PET imaging for detecting invasive lobular carcinoma. The study aims to assess the ability of FAPI PET and FDG PET to detect tumors and evaluate its impact on patient care.
Researchers discovered rare cases of prostate cancer spreading to the testicles using advanced PSMA PET/CT scans, changing how doctors monitor recurring prostate cancer. A new ultra-low-dose PET scanning method reduced radiation exposure without compromising diagnostic image quality in cancer and metabolic imaging.
Dr. Romina Mizrahi's PET-based neuroimaging sheds light on brain workings, integrating genetics, environment and imaging to understand psychiatric illness as a complex biological puzzle. She advocates for precision psychiatry paradigm with customized treatments based on molecular profiles, and calls for diversity in academic leadership.
Two new studies published in The Journal of Nuclear Medicine explore innovative approaches to treating melanoma with radiation therapy and enhancing brain PET imaging. A third study validates an AI network for brain tumor imaging, demonstrating promising results.
The new Keck Medicine of USC – Newport Beach Radiation Oncology and Imaging Center offers biology-guided radiation therapy, using up-to-the-minute signals to track and treat cancer cells in real time. The center is equipped with state-of-the-art technology and will be the first in Orange County to provide this treatment option.
A novel PET imaging approach has effectively quantified the COX-2 enzyme in human brains, opening doors for its use in clinical settings for various brain disorders. This breakthrough could lead to earlier disease detection and monitor disease progression with anti-inflammatory treatments.
Researchers have confirmed a neurobiochemical link between dopamine and cognitive flexibility through PET imaging, showing increased dopamine production with cognitively demanding tasks. This finding may lead to the development of more precise treatment strategies for neurological and psychiatric disorders.
A study confirms plasma p-tau217 as a blood-based biomarker for early Alzheimer's detection in Asian populations. Higher levels correlate with faster cognitive decline, suggesting its potential role as both diagnostic and predictor tool.
A new PET radiotracer effectively visualizes Nectin-4, a biomarker found in triple-negative breast cancer (TNBC), with the potential to improve clinical outcomes. Researchers developed a series of Nectin-4-targeted radiotracers and evaluated their efficacy in detecting TNBC.
Scientists repurposed the drug edaravone as an imaging probe to detect oxidative stress in brain tissue using PET scans. This technique can help diagnose neurological conditions such as ALS and Alzheimer's disease earlier, when treatment is more effective.
A new PET tracer has been developed to visualize intact nerve connections in the spinal cord, which may indicate a better chance of recovery. This breakthrough has the potential to help diagnose injuries more precisely, monitor recovery, and evaluate the effectiveness of new therapies.
Next-generation tau radiotracers demonstrate higher binding to Alzheimer's disease brain tissue and greater selectivity than existing imaging agents. This could lead to improved diagnosis and staging of the disease, as well as better outcomes in clinical trials.
Research at Turku PET Centre found elevated opioid neurotransmitter activity in anorexia patients' brains, linked to increased appetite regulation and emotional symptoms. The study suggests changes in brain function may explain the emotional symptoms and mood changes associated with anorexia nervosa.
The Society of Nuclear Medicine and Molecular Imaging has issued a new procedure standard/practice guideline for the use of fibroblast activation protein (FAP) PET, outlining indications, imaging procedures, and quality control/quality assurance procedures. The guideline aims to deliver diagnostic efficacy and study quality for patients.
Researchers found AI-based imaging technology improves disease diagnosis accuracy, particularly in cardiology, oncology, neurology, and ophthalmology. The technology also enhances diagnostic efficiency and reduces healthcare disparities by delivering high-quality diagnostics to underserved areas.
A new PET approach has detected early signs of tissue remodeling in patients with pulmonary arterial hypertension, providing an early marker for disease progression. This could pave the way for more personalized management and timely interventions to improve patient prognosis.
A new study found that nearly half of high-risk prostate cancer patients have metastatic disease when evaluated with advanced PSMA-PET imaging, suggesting traditional imaging may underestimate cancer spread. This challenge the interpretation of previous studies like EMBARK trial, and support the inclusion of PSMA-PET for patient select...
Researchers have developed a new scan that lights up aggressive cancer tumors, allowing doctors to target and treat cancer more effectively. The scan uses a radiotracer to show treatment-resistant tumours on PET scans, giving patients alternative options for better survival rates.
A novel radiotracer has accurately identified a crucial cancer biomarker, Trop2, found in various types of cancer. The radiotracer, <sup>18</sup> F-AlF-RESCA-T4, enables precise visualization of Trop2 expression and can differentiate lung inflammation from cancer.
A phase 2 study conducted by Mayo Clinic found that 56% of participants were alive after 12 months, with a median overall survival of 13.1 months. The treatment, which combines short-course hypofractionated proton beam therapy with advanced imaging techniques, was more effective in patients over 65 with favorable tumor genetics.
A Chinese Medical Journal study reveals that patients with prostate cancer can undergo surgical removal without a pre-operative biopsy, using a combination of mpMRI and PSMA PET/CT imaging. This approach reduces costs and complications associated with traditional biopsy methods.
A new PACT system offers rapid imaging of living organisms, enabling the tracking of whole-body dynamics and disease progression. The system achieves spatial resolution of approximately 212 micrometers and enables the visualization of oxygen saturation across complex biological systems.
Dr. Volkow emphasizes the importance of prevention strategies and research on stress, trauma, and social determinants in substance use disorders. She also highlights promising new directions in treatment, including GLP1 medications, to address the treatment gap in addiction.
Researchers developed a method to visualize AMPA receptors using PET scans, revealing differences in density and distribution between healthy subjects and those with psychiatric disorders. This discovery may lead to new diagnostic and therapeutic approaches for conditions like schizophrenia, bipolar disorder, and autism spectrum disorder.
Researchers will develop a high-resolution PET scanner that can accurately detect amyloid plaques and tau tangles, enabling earlier diagnosis of Alzheimer's disease. The portable scanner aims to improve accessibility and portability for underserved communities.
Researchers developed a new PET scan that accurately visualizes benign tumors in the pancreas, known as insulinomas, which can cause low blood sugar levels. The Exendin-PET scan uses a substance found in lizard saliva to detect these tumors, improving diagnosis and treatment outcomes.
A recent study found that tau protein buildup disrupts the salience network, a crucial communication network in the brain, leading to behavioral changes. The study used advanced medical imaging to analyze the brains of 128 people with early-stage dementia and showed a strong association between tau disruption and behavioral symptoms.
A novel PET/CT technique has been developed to detect neuroblastoma in children with high sensitivity and short scan time, eliminating the need for sedation or anesthesia. The new technique uses a novel tracer and next-generation scanner, resulting in improved diagnostic accuracy and reduced radiation exposure.
Researchers at WVU created a motion-compatible brain scanner that allows patients to move around during imaging. The Ambulatory Motion-enabling PET (AMPET) scanner can help study human behaviors, balance, and emotions, and may be used to monitor brain activity for PTSD treatment and mindfulness meditation.
A new hybrid contrast agent has been developed to combine the benefits of MRI and PET imaging techniques, offering improved accuracy and opening new diagnostic applications. The agent has shown potential in detecting kidney problems and other conditions, paving the way for personalized diagnostics and precise imaging.
A newly developed granzyme B PET imaging method can non-invasively detect IBD and provide a real-time picture of active inflammation. This technology could guide personalized patient management strategies and monitor treatment efficacy.
The study establishes criteria for identifying extranodal extension on imaging, allowing radiologists to make accurate calls and provide patients with less invasive treatments. This shift towards practice change has the potential to reduce side effects and improve outcomes for patients with HPV-associated head and neck cancers.
The study compared FDG-PET/CT and CT for evaluating treatment response in unresectable malignant pleural mesothelioma patients. The results showed that both imaging modalities provided accurate findings for tumor response evaluation, with high concordance between the two methods.
A new liquid biopsy method analyzes gene fragments in the bloodstream to detect and track cancer, enabling oncologists to tailor treatment approaches to individual patients. This non-invasive test can help monitor treatment success, detect cancer recurrence, and improve patient quality of life.
A phase 2 study found fluorine-18 PSMA-1007 PET/computed tomography to be superior to multiparametric MRI for locoregional staging of prostate cancer. The technology supports its use in the preoperative workflow for intermediate-risk and high-risk tumors.
Researchers explore the feasibility of deep learning models in segmenting lesions on PET/CT images to improve salvage radiation therapy planning for prostate cancer. The study demonstrates promising potential to reduce inter- and intra-observer variations, leading to more accurate treatment outcomes.